$300 Hep C Cure Just as Good as $84,000 Alternative

Non-profit organization DNDi has developed a low-cost hepatitis C treatment that stands to benefit 71 million people.

Protesters / Image: Josep Lago
Protesters / Image: Josep Lago

A recent article from The Guardian had good news for the 71 million people affected by hepatitis C, the blood-borne viral infection that causes 400,000 deaths a year. The non-profit Drugs for Neglected Diseases initiative (DNDi) has teamed up with Egypt’s Pharco Pharmaceuticals to create a two-pill treatment for the disease that’s expected to cost just $300.

The drugs, ravidasvir and sofosbuvir, are a welcome alternative to versions from Gilead and AbbVie, which can cost up to $84,000. The DNDi reported that the new treatment cured 97% of patients within 12 weeks.

Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground
Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026